Analysis of the main efficacy and clinical effects of Enasidenib

Enasidenib is an oral small molecule targeted drug. Its core mechanism is to selectively inhibit the activity of IDH2 mutant enzyme. IDH2 mutations can lead to an abnormal increase in intracellular 2-hydroxyglutarate (2-HG) levels. This metabolic abnormality blocks the differentiation of leukemia cells, causing a large accumulation of pathological immature cells and promoting the progression of acute myeloid leukemia. Ensidipine inhibits the activity of IDH2 mutant enzyme and reduces the accumulation of 2-HG, thereby restoring the differentiation ability of leukemia cells and gradually transforming them into mature blood cells, thereby inhibiting the course of the disease and improving hematological indicators.

In clinical practice, ensidipine is mainly used for patients with relapsed or refractory acute myeloid leukemia (AML). Compared with traditional chemotherapy, its targeted nature means lower toxicity to normal cells and relatively controllable side effects. Common manifestations include differentiation syndrome, hematological toxicity, and mild to moderate gastrointestinal reactions. Ensidipine can be used as a single agent or in combination with low-intensity chemotherapy or other targeted drugs to enhance efficacy and improve patients' quality of life. At the same time, the application of the drug embodies the concept of precision medicine: only patients who are confirmed to be mutation-positive through IDH2 gene testing can obtain the maximum therapeutic effect, which helps to reduce unnecessary drug exposure and potential toxicity.

In addition, ensidipine has shown certain advantages in long-term management of AML patients. By sustainably inhibiting IDH2 mutant cells, delaying leukemia relapse and improving hematological function, the drug provides patients with a relatively tolerable treatment option. In the future, with the deepening of clinical trials and the optimization of combination therapy strategies, the role of ensidipine in the treatment of relapsed or refractory AML may be further expanded, bringing more precise and controllable treatment options to patients.

Reference materials:https://www.idhifa.com/